Member Info for Tiger16

Nobby I have all my chips now in this and WSBN .. I feel they are going to be , shock the market ..

I agree Cando 66 , however as I have sold out of IMM and gone in heavy here , I am a little nervous only as what if these results we are waiting for are not what we are all expecting ????

Well guys as we wait patiently , and I agree this is not one of those stock you can jump out of even for a second .. we do not know when , they could drop the mother of all RNS es any second ... and its rocket ... In the mean time , I will confess , I dont see a problem with those who share other stocks , I dont feel its cross ramping , as I know we are all guilty of on some occasions acting upon information shared .. I have made a few bags here and there on shared information .. so thank you to those who do ....

Guys I came in today with 13 and half k , as all I can say is this is a once in a lifetime opportunity on Aim . That’s all is can say . There will be no RNS tomorrow. We will got to 2 p expect Monday to be one of the biggest days of our lives z

If there is no RNS tomorrow it will be the last opportunity In my opinion to get in before 2 p ..

Red Setter (WSBN):

• About 13 km southwest of Newcrest Mining’s Telfer Mine.

• Within the same geological corridor (Paterson Province).

• The Paterson Province is highly prospective for gold and copper mineralisation.

• Greatland Gold’s Havieron (GGP):

• Discovered in 2018.

• Roughly 45 km east of Telfer.

• Newcrest (now Newmont after acquisition) partnered with GGP to develop it into a major new underground gold-copper mine.

• Havieron turned GGP from a penny stock into a multi-billion pound company.

⸻

🌍 Why This Matters for WSBN

1. Geological Similarity

• Both Red Setter and Havieron sit within the same structural corridor and share geological features:

• Breccia pipes.

• Sulphide mineralisation.

• Quartz-carbonate veining.

• This fuels speculation that Red Setter could host a Havieron-like deposit.

Hence it is all most certain insider are buying here as they know what’s coming.. and who will JV or buy them out ..

Thanks for the advice , I followed your string and and 13 .5 k invested .. at 1.47 .. this is looking good ..

NT TO BUY NOW .. OMG , LOOKS LIKE A LEAK WHEN YOU CANT BUY ....

I bought IMM at 4.44 and payed £9537.00 for 225, 853 shares and sold for 6 p , thats not £ 50 profit and i posted my buy seconds latter .. so it is real , I have just bought WSBN 1.47 q 917. 535 , £13557.00...

I will be back here in 4 weeks when the SP IS UNDER 5 P , WITH MY PROFIT FROM WSBN WHICH HAS RESULTS COMING IN DAYS AND GOLD IS CLIMBING , AND IT WAS A TIP FROM SOMEONE , THAT ALL I CAN SAY .. I COULD OF GOT THIS ALL WRONG .. PLEASE ALL DO YOUR OWN RESEARCH , ITS COMMON SENSE THAT A DEAL IS IN THE MAKING , BUT WONT BE DONE OVER NIGHT OR IN A FEW WEEKS WHILE SHE SHARE PRICE DROPS .. GOD BLESS ALL ...

Mavrick I see your points he did say he was not hounding to raise again in the last interview and then he did . Yet he now has said the same , which for me or he does it’s criminal .. I feel a pull back now .. as this still needs time .. I’m holding . Don’t have the ticker to to be out of this now .

My question is guys how do we know the assay results are going to be good , if they are not this will tank ana clearly if they are good it will e re rate .

Anyone pls , do we have enough research to know what to expect

Just for that one poster I have not sold .. and wont be .. it wont go up in a straight line .. its common sense , some here have made 200 per cent .. they will sell .. I am a real investor looking for the buy out .. which will take time now .. we need to hold for a several weeks while the Patient gets registered and Neg take a advanced stage which was not mentioned in the Interview hence once we receive the RNS thats advises NDA and advanced stage take or JV this is going through the roof ..

Massive sell coming now ,tree shake I think .. I am holding .. as long as we stay above 5 p .. yet It looks like it will drop back now .. USA open around the corner .. DYOR .. My opinion is we are going to fall back , bit of a spike .. yet I am holding for gold ..

WELL guys we did it .. congrats guys we are on our way .. now its all about staying focused and having nerves of steal .. I see a pull back as traders take profit level 2 showing sells now .. I am holding , let it drop so I can buy more .. end of ..

Guys I will be adding 35 k tomorrow as I have placed a buy order at 4p knowing some idiots will sell out or the Mm will take stop losses .

If anyone has over 50 k in this they will make life changing money .. AIM this is the best one that comes around once a decade ..

Good luck all

Guys there is always a pull back after a150 per cent rise at one point yesterday However is the trades selling or the MM holding it back for sellers to sell , the weak hands , so they can make more once the flock of buyers come back in .

No placing

No dilution

We saw how fast the share price rocketed yesterday.

The deal is in the making and can drop anytime now ..

It seems they have another drug in the pipeline as well .. 10 p will be incoming in the next few sessions and then it will consolidate at the level until the big news arrives where no one will get a chance to buy , as it will be suspended from trading due to a take over or buy out .. end of journey ..

My city friends see no JV a complete buy out is on the cards here and it’s small change for a big pharmaceutical standing to make billions of this .

Why would IMM file a patent unless they knew the drug was the real deal?

Think about it… companies don’t waste time and money filing a patent unless:

1. They already have solid scientific evidence – you can’t protect something without a strong body of research behind it. P140 has already shown real results in human biology.

2. They believe the commercial potential is massive – patents are about locking in exclusivity. IMM is aiming for 20 years of protection in a market worth over $100 billion annually. You don’t do that for something small.

3. They know big pharma will take notice – this is how partnerships and takeovers start. A patent makes the asset clean, protected, and attractive for licensing or acquisition.

⸻

Bottom line: IMM wouldn’t be applying for a patent unless P140 had been tested to a level that makes it valuable. This isn’t small change – this is potentially a multi-billion dollar drug and IMM are making sure they own the rights.

Guys anyone with any research experience and investment knowledge would realise that this news is significant and investing now is how real money is made risk vs reward , I sold out of here months ago as I listen to the talk , yet knew until we have a patient this is not real . Now it is real and happening in real time just by the promotion of our scientists was a clear message they won’t control of negotiations now ..

We had a significant rise yesterday by a 10 per cent drop .. and most think this is a pump and dump.. no this is how stocks do 500 per cent in a week .. we needed a pull back that the MM are willing to buy significant amount of shares back at the price they want , as they know how to fill gaps ..

They are taking all my holding £9500 k worth .. hello .. MM collecting shares .. the gap is about to be filled ...

A lot of people are under the impression that the U.S. doesn’t matter here – but that’s simply not true. U.S. investors will be looking at IMM closely after yesterday’s RNS, and here’s why:

1. Biotech is where U.S. investors focus – The American market is home to the biggest biotech funds and retail traders who actively seek early-stage innovation stories. IMM’s new patent application around P140 puts it in the same conversation as other cutting-edge autoimmune plays.

2. Access is not a barrier – Even though IMM isn’t on OTC, many U.S. investors have brokers (Interactive Brokers, Fidelity International, Schwab Global etc.) that give them direct access to the London market. If they want in, they can buy the shares exactly as they are.

3. Global attention on autoimmune breakthroughs – The potential market for P140 is huge: autoimmune disease treatments represent a $100bn+ sector. U.S. biotech investors understand the scale and are used to paying up for first-in-class drugs.

4. Price momentum attracts U.S. traders – Once news circulates and price action kicks in, momentum itself becomes a magnet for overseas traders who don’t want to miss the move.

⸻

Bottom line: The RNS has put IMM on the radar of U.S. biotech investors. They will be buying—through international broker access—and their demand has the potential to add real fuel to the share price here in London.